News
Video
Author(s):
Dr. Gadgeel reviews the HERTHENA-Lung01 trial results of the HER3 targeting antibody drug conjugate patritumab deruxtecan in EGFR-positive non-small cell lung cancer.
Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Frontline Osimertinib Plus Chemo Wins Canadian Approval for EGFR+ Advanced NSCLC
Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
Best Practices in Treating Early-Stage NSCLC
European Commission Approves Osimertinib Plus Chemo for Advanced EGFR+ NSCLC
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC
Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer
Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium